Compare Target Corporation (TGT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Zoetis Inc — how do they compare? Target Corporation trades at $153.77 (market cap $70.31B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Target Corporation is far larger — about 2.3× Zoetis Inc's market cap, and Target Corporation pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Zoetis Inc for 70 Days on average.
| TGT | ZTS | |
|---|---|---|
Market Cap | $70.31B | $30.20B |
Volume | 4,164,999 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $147.53 |
52-Week Low | $83.68 | $69.09 |
Typical Hold Time | 137 Days | 70 Days |
Enterprise Value | $83.58B | $37.76B |
Dividend Yield | 3% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target (TGT) trades at $153.77, up 1.86% today, with a bearish technical signal but strong fundamental support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 estimate. Valuation ratios like a P/E of 16.05 and P/S of 0.65 appear attractive relative to historical averages. Recent news highlights strategic price cuts on 2,000 items to boost holiday sales and market share.
The outlook is cautiously optimistic, supported by solid profitability, dividend reliability, and analyst consensus pointing to upside. Key risks include competitive pressures, margin compression from pricing strategies, and broader retail sector volatility. The consensus price target of $167.18 suggests potential appreciation, but investors should weigh execution risks against growth initiatives.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
